Hottest Stocks in CW 35/24

Masterflex stock has now successfully concluded the correction that began in mid-June and lasted two months, with its share price rising by around 9 % last week.

The developer, manufacturer and processor of spiral hoses is apparently continuing to benefit from the figures for the second quarter that were published almost three weeks ago. The company reported a moderate increase in turnover and a net profit that was more than twice as high. The forecast for the year as a whole was also upheld.

Stephan Pflug (Leise) invested in Masterflex last week, implementing the strategy of a successful fund manager in his extremely popular wikifolio Qualität, angelehnt an Susan Levermann. She presented her selection criteria in the book “Der entspannte Weg zum Reichtum” (The relaxed path to wealth), providing many traders with a good template for their own trading ideas. In short, the concept involves evaluating companies according to a total of twelve different (mostly fundamental) aspects that have historically indicated above-average future performance. Masterflex has now performed so well that the stock has been selected for this portfolio.

Bavarian Nordic, which specializes in the development, production and marketing of cancer immune therapies and vaccines for the prevention and treatment of infectious diseases, has been one of the most traded stocks on wikifolio.com in recent weeks. Over a period of one month, 458 trades were made in the Danish stock, over twice as many as in the previous eleven months. What is striking here is the relatively even balance between Buys and Sells, which indicates that the traders here are mostly active on a short-term basis. However, given the strong price fluctuations of the past few days, such strategies naturally also make sense.

Trading-Sentiment:

The fact that Bavarian Nordic is suddenly being so heavily traded is undoubtedly due to the so-called “monkeypox virus”. The World Health Organization (WHO) had recommended expanding the production of vaccines against the Mpox virus after a new variant of the infectious disease emerged in Africa. On Friday, the WHO declared that its partners such as Gavi and Unicef may begin purchasing Mpox vaccines to provide aid to Africans before they are licensed.

The Bavarian Nordic vaccine is already licensed in Europe and the USA and has been in use since 2022. In the United States, around 1.2 million people have been vaccinated with it so far. wikifolio trader Christian Scheid (Scheid) is (of course) already invested in the stock and has already made some successful short-term speculations. And the next trade is already in progress. In his very successful wikifolio Special Situations long/short, the stock is currently even the largest position. “Due to expected orders, there is sufficient news flow - I have bought again and may want to add to it,” wrote the financial journalist this morning.

Apart from a comparatively attractive dividend, the chemical company BASF has not had much to offer its shareholders in recent years. The share price has more than halved in value since peaking at around € 100 at the beginning of 2018 and attempts at a sustainable recovery have since regularly fizzled out. Most recently, the share price rose to over € 55 in April, only to slump again to just over € 40. The company's results have so far failed to provide that decisive push. The figures for the second quarter published at the end of July were dominated by the Group's low retail prices. Revenue fell by around 7 % compared to the previous year, while operating profit was roughly at the same level as in 2023. Nevertheless, the Management Board upheld its forecast for the year, although Q2 earnings fell just short of analysts' expectations.

In August, BASF stocks are once again presenting themselves from their good side, with gains of over 10 % so far. This is despite a fire breaking out at the Ludwigshafen site, which led to supply bottlenecks and prompted analysts at Goldman Sachs to update their estimates for the Food Ingredients and Supplements division. Last week, on the other hand, BASF's own CFO, Dirk Elvermann, bought BASF shares at € 42.61 for a good € 55,000. The CFO seems to be just as confident as the majority of analysts. They see the fair value of BASF stock as a good 16 % higher than it is currently.

On wikifolio.com, some traders have nevertheless used the recent price increase to pull out. Moritz Mühle (Mozimiller) took this step even though the share “actually looks attractive” to him at the current price level. However, this does not play a role in the decisions made in his wikifolio Performance powered by AI. The responsibility here lies with artificial intelligence (AI). “AI has given BASF a sell rating today and so we have got out”, comments the trader, adding: “AI assesses the short-term probability of beating the market”.

Weak figures and a lowering of the competitor Doc Morris' annual forecast negatively impacted Redcare Pharmacy stock last week. Overall, the stock recorded almost double-digit losses. The downturn was accelerated by a negative evaluation by UBS analysts. The Swiss firm sees the fair value of its stock at only € 83. Despite the recent setbacks, the company, which formerly traded under the name Shop Apotheke Europe, is currently still trading at over € 120.

A few weeks ago, large-scale insider sell-offs by Management Board member Theresa Holler were particularly noteworthy. Shortly before this, the company itself had reported a significant increase in operating profit in the past quarter, but still had to report losses below the bottom line. After the stock had trended sideways to downwards in recent weeks, the majority of wikifolio traders active here recently sold the stock. In the last seven days, the percentage of Sells was 82%, and 66% for the month as a whole.

Trading-Sentiment:

“Stock sold off. Wait for further setbacks to get back in”, wrote Manfred Wagner (oekethic), for example, who was still able to realize a profit of around 9 % in his Redcare Pharmacy wikifolio oekethic Nachhaltigkeit.

Disclaimer: Every investment in securities and other forms of investment is subject to various risks. Explicit reference is made to the risk factors in the prospectus documents of Lang & Schwarz Aktiengesellschaft (Final Terms, Base Prospectus together with supplements and the Simplified Prospectuses, respectively) at wikifolio.com , ls-tc.de and ls-d.ch. You should read the prospectus before making any investment decision in order to fully understand the potential risks and rewards of the decision to invest in the securities. The approval of the prospectus by the competent authority should not be construed as an endorsement of the securities offered or admitted to trading on a regulated market. The performance of the wikifolios as well as the respective wikifolio certificates refers to past performance. Future performance cannot be inferred from this. The content of this site does not constitute investment advice or a solicitation to buy or sell securities. This applies in particular to countries in which such an offer to buy or sell is not permitted. For further information, please refer to our General Terms and Conditions.